Dimethyl sulfoxide-frozen platelets demonstrated equivalent hemostatic efficacy to standard liquid-stored platelets in controlling bleeding during cardiac surgery, according to a randomized clinical trial. The cryopreserved platelets achieved similar rates of bleeding cessation and required comparable transfusion volumes, while maintaining safety profiles consistent with conventional platelet therapy. This equivalence carries significant implications for blood banking logistics and emergency preparedness. Cryopreserved platelets can be stored for years rather than the 5-7 day shelf life of liquid platelets, potentially revolutionizing inventory management in hospitals with irregular cardiac surgery volumes or remote locations. The extended storage capability could prove particularly valuable during supply shortages or mass casualty events where fresh platelet availability becomes constrained. However, the study's focus on cardiac surgery patients limits broader applicability to trauma, cancer, or other bleeding scenarios. The cryopreservation process also requires specialized equipment and protocols that may challenge implementation in resource-limited settings. While this represents an incremental but meaningful advance in transfusion medicine, widespread adoption will depend on cost-effectiveness analyses and regulatory approval pathways for routine clinical use.